ProfileGDS5678 / 1424668_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 59% 60% 57% 60% 56% 58% 58% 59% 60% 60% 59% 60% 59% 60% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6000459
GSM967853U87-EV human glioblastoma xenograft - Control 23.5736560
GSM967854U87-EV human glioblastoma xenograft - Control 33.4397157
GSM967855U87-EV human glioblastoma xenograft - Control 43.5501960
GSM967856U87-EV human glioblastoma xenograft - Control 53.3764856
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5847558
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5898358
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5597759
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.560860
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.5615260
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.5574959
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5672160
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5726559
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5611160